Secondary ocular hypertension after intravitreal injection with 2 mg or 4 mg of triamcinolone in retinal vein occlusion

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Lan-Hsin ChuangChi-Chun Lai

Abstract

To evaluate secondary ocular hypertension after intravitreal injection of triamcinolone acetonide (IVTA) with 2 mg/0.05 mL or 4 mg/0.1 mL for macular edema associated with retinal vein occlusion (RVO). A retrospective chart review was performed. Patients with RVO, including central RVO and branch RVO, were divided into 2 groups. Group 1 was patients who received 2 mg IVTA and group 2 received 4 mg IVTA. The dose of IVTA was dependent on individual surgeon's decision. Secondary ocular hypertension was defined as intraocular pressure (IOP) >21 mmHg. Long-term antiglaucoma medication referred to eyes that required antiglaucoma agents for >6 months. Thirty-six eyes in group 1 and 32 eyes in group 2 were included in the analyses. The mean age of all the patients was 58.6 years, and 52.9% of patients were men. The mean follow-up period was 12.4 months. A wide range (from day 7 to month 8) of time until the onset of the IOP spike was recorded after the injection. The incidence of secondary ocular hypertension was not significantly different between group 2 and group 1 (38.9% vs. 50%, P = 0.36). However, group 2 had a higher proportion of long-term antiglaucoma medication usage than group 1 (5.6% vs. 40.6%; Pearson chi-square, P < 0.00...Continue Reading

References

Sep 1, 1987·Annals of Surgery·J Folkman, D E Ingber
Sep 15, 1984·American Journal of Ophthalmology·A Patz
Aug 1, 1982·Ophthalmology·M O Tso
Nov 30, 2002·Journal of Cataract and Refractive Surgery·Jost B Jonas, Antje Söfker
May 14, 2003·Archives of Ophthalmology·Jost B JonasRobert Degenring
Aug 4, 2004·American Journal of Ophthalmology·Inder P SinghPaul P Lee
Oct 19, 2004·American Journal of Ophthalmology·Shishir AgrawalTrilok Prakash Agrawal
Apr 30, 2005·American Journal of Ophthalmology·Tom H Williamson, Annie O'Donnell
Sep 16, 2006·The British Journal of Ophthalmology·Dennis S C LamMahesh P Shanmugam
Sep 19, 2006·American Journal of Ophthalmology·François AudrenPascale Massin
May 17, 2007·The British Journal of Ophthalmology·Masafumi OtaNagahisa Yoshimura
Dec 11, 2008·Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye·Daniel B RothJonathan Prenner
Mar 11, 2009·Archives of Ophthalmology·UNKNOWN Diabetic Retinopathy Clinical Research Network (DRCR.net)Craig Kollman
Jun 10, 2009·Archives of Ophthalmology·Roy W Beck

❮ Previous
Next ❯

Citations

Dec 15, 2010·Advances in Therapy·Ahmad A Aref, Ingrid U Scott
Jul 14, 2012·Clinical Ophthalmology·D Wilkin ParkeTimothy G Murray
Jun 19, 2013·Survey of Ophthalmology·Weerawat KiddeeYvonne M Buys
Nov 18, 2016·Indian Journal of Ophthalmology·Avirupa GhoseJyotirmoy Biswas
Oct 15, 2011·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Ji Won LimMin Cheol Shin
Jul 16, 2011·Ophthalmic Research·M Reza Razeghinejad, L Jay Katz
Oct 12, 2018·Retina·Philip P StoreyCarl Regillo
Sep 10, 2015·The Cochrane Database of Systematic Reviews·Dina GewailyPaul B Greenberg

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.